MoneyWorks4Me

The September 2023 quarter revenue stood at Rs. 8367.60 millions, up 13.08% as compared to Rs. 7399.60 millions during the corresponding quarter last year.An average growth of 48.40% was recorded for the quarter ended September 2023 to Rs. 1450.20  millions from Rs. 977.20 millions.The company reported a good operating profit of 2416.80 millions compared to 1675.10 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 8367.60 7399.60 13.08 16893.40 14560.90 16.02 28841.60 21898.80 31.70
Other Income 68.40 17.20 297.67 119.70 22.30 436.77 86.50 386.10 -77.60
PBIDT 2416.80 1675.10 44.28 4816.40 3360.00 43.35 6733.40 5475.20 22.98
Interest 94.60 76.00 24.47 206.70 133.90 54.37 343.10 49.50 593.13
PBDT 2322.20 1599.10 45.22 4609.70 3226.10 42.89 6390.30 5425.70 17.78
Depreciation 315.00 277.10 13.68 621.50 534.00 16.39 1119.90 712.80 57.11
PBT 2007.20 1322.00 51.83 3988.20 2692.10 48.14 5270.40 4712.90 11.83
TAX 557.00 344.80 61.54 1092.30 702.00 55.60 1381.50 1102.90 25.26
Deferred Tax 132.70 111.30 19.23 265.70 228.50 16.28 548.00 -122.10 -548.81
PAT 1450.20 977.20 48.40 2895.90 1990.10 45.52 3888.90 3610.00 7.73
Equity 155.00 154.70 0.19 155.00 154.70 0.19 154.80 154.60 0.13
PBIDTM(%) 28.88 22.64 27.59 28.51 23.08 23.55 23.35 25.00 -6.62
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..